A breakthrough technology or the end of animal testing?
The pharmaceutical landscape is currently struggling with multifaceted challenges, such as poor solubility and low bioavailability of molecules during drug development, consequently increasing drug product complexity. Existing computational models and animal studies fall short of capturing the complexity of drug dissolution and absorption. This underscores the growing need for innovative methodologies and advancements in predictive techniques to enhance the understanding of drug behavior within the human gastrointestinal tract and technologies to enhance such a delivery.
In response to this industry demand, InnoGI Technologies presents its expanded product portfolio, the SurroGUT™ Platform. This technology is designed to replicate the human GI tract authentically, combining state-of-the-art technology with advanced digestive fluids secreted at true-to-life rates to mimic the dynamic environment of the human GI tract with high fidelity.
InnoGI, formerly known as The TIM Company, is more than just an ordinary technology, it is a revolutionary system. In 2016, First Dutch acquired the innovative TIM system from TNO portfolio. Although TNO had invested heavily in the technology, it still needed to be brought to market when First Dutch took over. Fortunately, First Dutch recognised it’s potential and invested heavily to continue its development, despite the high costs and uncertainties.
Thanks to these investments, we have avoided over 5000 animal tests today and has grown into a thriving company with around 40 employees. As a result, InnoGI is paving the way for a future of innovation in which sustainability and ethics are at the forefront.
